Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

BACKGROUND: The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation therapy is still discussed controversial. We applied metronomic chemotherapy in the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Thorsten, Hero, Barbara, Faldum, Andreas, Handgretinger, Rupert, Schrappe, Martin, Klingebiel, Thomas, Berthold, Frank
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031264/
https://www.ncbi.nlm.nih.gov/pubmed/21244693
http://dx.doi.org/10.1186/1471-2407-11-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031264/
https://www.ncbi.nlm.nih.gov/pubmed/21244693
http://dx.doi.org/10.1186/1471-2407-11-21

Ejemplares similares